Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
Latest Information Update: 25 May 2026
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 27 Mar 2026 Planned End Date changed from 14 Feb 2026 to 14 Feb 2027.
- 27 Mar 2026 Planned primary completion date changed from 14 Feb 2026 to 14 Feb 2027.
- 28 Nov 2024 Planned End Date changed from 14 Feb 2025 to 14 Feb 2026.